Treatment of Chronic Prostatitis with Phosphodiesterase Type 5 Inhibitors

Abstract

Our major aim was to systematically study the effectiveness of phosphodiesterase type 5 inhibitors in treating chronic prostatitis stage III and performed meta-analysis to evaluate the changes occurred in posttreatment scores of National Institutes of Health chronic prostatitis symptom index, international index of erectile function and international prostate symptom score. This meta-analysis was conducted according to the preferred reporting items for systematic reviews and meta-analyses guidelines. Comprehensive research was performed by using online resources like PubMed and the Wiley online library database to gather the relevant literature produced from the y 2010 to 2022. Two authors were assigned to independently collect the relevant information including author name, region of study, study design, treatment, publication year, sample size, voiding parameters, study inclusion and exclusion criteria, urological conditions, drug type, international prostate symptom score, international index of erectile function score, etc. In final screening 17 relevant studies were found. Out of these 17, 5 contained surgical procedure while 4 were narrative analysis. One study was incomplete regarding information. Finally, 7 studies were included for analysis. Total of 584 patients were involved in the selected studies. Three out of seven are from Italy region while two are from Japan and one was from Korea and Egypt respectively. Most of these studies used tadalafil monotherapy while one placebo-controlled trial. A significant difference in pain score, international prostate symptom score domain and National Institutes of Health chronic prostatitis symptom index were observed after consuming 5 mg tadalafil monotherapy. Everyday consumption of oral phosphodiesterase type 5 gave positive outcomes in terms of voiding. A significant difference was observed after using tadalafil monotherapy in the majority of the studies. Hence, tadalafil alone can be used to treat the type III chronic prostatitis.

A combined electrohydrodynamic atomization method for preparing nanofiber/microparticle hybrid medicines

“…In clinics, doctors often combine traditional Chinese medicines with Western medicine and antibiotics for improved therapeutic effects on patients with chronic bacterial prostatitis. However, the complexity of medication methods can cause inconvenience for patients ( Alzahrani et al, 2022 ; Bouiller et al, 2022 ; Kuiper et al, 2022 ; Marino et al, 2022 ). We propose that these medicines could be integrated into a single medical material, improving drug delivery effectiveness and functional performance through controlled release profiles.…”